Literature DB >> 1588793

Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop.

H Jernberg-Wiklund1, M Pettersson, M Carlsson, K Nilsson.   

Abstract

A human multiple myeloma (MM) cell line, U-266, has developed the ability to grow independently of exogenous interleukin 6 (IL-6) during long-term cultivation in vitro. The early passage, feeder-cell dependent U-266 cell line (U-266-1970) was compared with the late passage U-266-1984 cell line with respect to response to IL-6, IL-1 beta and tumour necrosis factor alpha and expression of IL-6 and IL-6 receptor (IL-6R) mRNA and protein. The results showed that; (a) only the U-266-1970 cell line was stimulated to growth by IL-6, (b) IL-6 and IL-6R mRNA were expressed in both cell lines, (c) the level of IL-6 mRNA was increased in the U-266-1984 cell line and only this line produced IL-6 and, (d) the level of IL-6R mRNA was highest in the U-266-1984 cell line and the number of IL-6R about ten times higher than in U-266-1970. The growth of the IL-6-producing U-266-1984 cell line was inhibited by 30% by anti-IL-6R antibodies suggesting the possibility that an autocrine IL-6 loop might have developed during the long-term cultivation. In addition to many other phenotypic alterations of the U-266 cell line, having developed as a consequence of tumor progression in vitro, its growth factor requirement seems to have evolved from a dependence on IL-6 as a paracrine growth factor to a capacity for autonomous growth, dependent on autocrine IL-6 stimulation. Whether such a development also may take place in MM clones in vivo remains to be established.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588793

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

Authors:  Caroline Bret; Dirk Hose; Thierry Reme; Anne-Catherine Sprynski; Karène Mahtouk; Jean-François Schved; Philippe Quittet; Jean-François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Br J Haematol       Date:  2009-03-02       Impact factor: 6.998

2.  Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.

Authors:  M Schwabe; A T Brini; M C Bosco; F Rubboli; M Egawa; J Zhao; G L Princler; H F Kung
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

3.  TNF-alpha and IL-6 induce differentiation in the human basophilic leukaemia cell line KU812.

Authors:  G Nilsson; M Carlsson; I Jones; S Ahlstedt; P Matsson; K Nilsson
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

Review 4.  Interleukin-6, a new target for therapy in multiple myeloma?

Authors:  M H van Oers; H C van Zaanen; H M Lokhorst
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

5.  Polycomb target genes are silenced in multiple myeloma.

Authors:  Antonia Kalushkova; Mårten Fryknäs; Miguel Lemaire; Charlotte Fristedt; Prasoon Agarwal; Maria Eriksson; Sarah Deleu; Peter Atadja; Anders Osterborg; Kenneth Nilsson; Karin Vanderkerken; Fredrik Oberg; Helena Jernberg-Wiklund
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240

6.  Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Authors:  Maria Rita Pitari; Marco Rossi; Nicola Amodio; Cirino Botta; Eugenio Morelli; Cinzia Federico; Annamaria Gullà; Daniele Caracciolo; Maria Teresa Di Martino; Mariamena Arbitrio; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2015-09-29

7.  MNK1-induced eIF-4E phosphorylation in myeloma cells: a pathway mediating IL-6-induced expansion and expression of genes involved in metabolic and proteotoxic responses.

Authors:  Yijiang Shi; Patrick Frost; Bao Hoang; Yonghui Yang; Carolyne Bardeleben; Joseph Gera; Alan Lichtenstein
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

8.  Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches.

Authors:  David Wong; Oliver Winter; Christina Hartig; Svenja Siebels; Martin Szyska; Benjamin Tiburzy; Lingzhang Meng; Upasana Kulkarni; Anke Fähnrich; Kurt Bommert; Ralf Bargou; Claudia Berek; Van Trung Chu; Bjarne Bogen; Franziska Jundt; Rudolf Armin Manz
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

9.  Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.

Authors:  Lina Y Dimberg; Anna Dimberg; Karolina Ivarsson; Mårten Fryknäs; Linda Rickardson; Gerard Tobin; Simon Ekman; Rolf Larsson; Urban Gullberg; Kenneth Nilsson; Fredrik Öberg; Helena Jernberg Wiklund
Journal:  BMC Cancer       Date:  2012-07-28       Impact factor: 4.430

10.  Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Authors:  Michela Colombo; Serena Galletti; Gaetano Bulfamante; Monica Falleni; Delfina Tosi; Katia Todoerti; Elisa Lazzari; Leslie A Crews; Catriona H M Jamieson; Sara Ravaioli; Francesco Baccianti; Silvia Garavelli; Natalia Platonova; Antonino Neri; Raffaella Chiaramonte
Journal:  Oncotarget       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.